Stomach Cancer Market Size, Share and Growth Outlook 2030
[Research Report] The stomach cancer market size is projected to grow from US$ 3,575.04 million in 2022 to US$ 10,751.42 million by 2030; it is estimated to record a CAGR of 14.8% during 2022–2030.
Market Insights and Analyst View:
Stomach cancer, also known as gastric cancer, is caused due to the abnormal and out-of-control growth of the malignant cells in the stomach. Risk factors that lead to the risk of stomach cancer include age and food. Indigestion, stomach discomfort, loss of appetite, heartburn, and weight loss are all symptoms of stomach cancer. Different approaches are employed in treating stomach cancers, such as chemotherapy, radiation therapy, and immunotherapy. The stomach cancer market growth is influenced by factors such as the growing incidence of stomach cancer, advancements in treatment, including chemotherapy, surgery, and targeted therapies, and ongoing research and development efforts to improve patient outcomes. With the increasing emphasis on early diagnosis and personalized treatment approaches, the stomach cancer treatment market is expected to continue to expand in the future.
Growth Drivers:
Businesses in the healthcare market are undertaking various research and development activities to introduce innovative treatments for gastric cancer. Additionally, the treatments are being evaluated in clinical trials, and new approaches are also being constantly developed and investigated through clinical trials. A few of the products in the pipeline are mentioned below:
- In December 2022, Zhejiang Doer Biologics Co., Ltd entered into a clinical trial collaboration agreement with Merck & Co., Inc., to evaluate Doer Bio's anti-Claudin18.2 antibody DR30303, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with gastric or gastroesophageal junction cancer. Under the terms of the agreement, Doer Bio conducted an experimental study based on a mutually- agreed and finalized protocol to investigate the safety and effectiveness of DR30303 in combination with KEYTRUDA in Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer patients.
- In November 2022, Triumvira Immunologics proclaimed preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, as well as data on HER2-specific TAC-T products. The company showed the updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 for treating gastric cancer.
- In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. Tumor volumes were measured for 28 days after mice in each group were treated with either a vehicle or NXP800 treatment. Tumor regression and significant tumor growth inhibition were the outcomes of NX800 treatment as compared to the control.
Therefore, the increasing number of clinical trials helps raise the availability of gastric cancer treatment worldwide, which, in turn, positively impacts the growth of the stomach cancer market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Stomach Cancer Market: Strategic Insights
Market Size Value in US$ 3,575.04 million in 2022 Market Size Value by US$ 10,751.42 million by 2030 Growth rate CAGR of 14.8% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Stomach Cancer Market: Strategic Insights
| Market Size Value in | US$ 3,575.04 million in 2022 |
| Market Size Value by | US$ 10,751.42 million by 2030 |
| Growth rate | CAGR of 14.8% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The stomach cancer market is segmented on the basis of type, treatment, route of administration, distribution channel, and geography. Based on type, the stomach cancer market is categorized into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. Based on treatment, the stomach cancer market is classified into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. The stomach cancer market, by route of administration, is segmented into oral, parenteral, and others. In terms of distribution channel, the stomach cancer market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the stomach cancer market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Segmental Analysis:
The stomach cancer market, by type, is categorized into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a significant share of the market in 2022 and is expected to register the highest CAGR in the stomach cancer market during 2022–2030.
Based on treatment, the stomach cancer market is categorized into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. In 2022, the chemotherapy and combination drugs segment held a significant share of the market. The targeted and immunotherapy drugs segment is expected to register the highest CAGR in the stomach cancer market during 2022–2030.
Based on route of administration, the stomach cancer market is segmented into oral, parenteral, and others. In 2022, the oral segment held a significant share of the market, and it is anticipated to record the fastest CAGR during 2022–2030.
Based on distribution channel, the stomach cancer market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant share of the market in 2022 and is expected to register the highest CAGR during 2022–2030.
Regional Analysis:
The stomach cancer market is primarily divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. In 2022, the US held the largest share of the market in the region. The market growth in North America is attributed to the growing prevalence of gastric cancer, increasing adoption of targeted cancer therapy, and the accessibility of advanced technology in cancer research and treatment centers. The American Cancer Society anticipated that ~26,500 new cases of gastric cancer (15,930 in males and 10,570 in females) will be diagnosed in 2023. ~11,130 deaths (6,690 males and 4,440 females) will be due to gastric cancer. North America is well-developed in terms of the accessibility of advanced technological treatment options for reducing cancer, and businesses are working hard to compete with the well-known players in the region.
Moreover, the increasing company activities in conducting clinical trials for the development of effective drugs for patients with gastric cancer and increasing product launches and approvals are estimated to fuel the market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-containing chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Thus, such factors are likely to support the market growth in the region during the forecast period.
Stomach Cancer Market Report Scope
Industry Developments and Future Opportunities:
Numerous initiatives taken by key players operating in the global stomach cancer market are listed below:
- In January 2021, AstraZeneca and Daiichi Sankyo Company received the approval of Enhertu from the US FDA for treating adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.
Competitive Landscape and Key Companies:
Bristol Myers Squibb Company; Novartis AG; Merck & Co., Inc.; Eli Lilly and Company; Biocon; Teva Pharmaceutical Industries Ltd; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Pfizer Inc.; and Ipsen Pharma are among the prominent players in the stomach cancer market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Treatment, Route of Administration, Distribution Channel, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The adenocarcinomas segment dominated the global stomach cancer market and held the largest market share of 45.34% in 2022.
The stomach cancer market majorly consists of the players such include Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company.
Stomach cancer is one of the leading causes of cancer-related deaths and the fifth most common malignancy worldwide. According to Globocan, around 1.1 million new cases of the disease were diagnosed worldwide in 2020. The increase in disease burden and approval of pipeline candidates are anticipated to propel the growth of the market during the forecast period.
The CAGR value of the stomach cancer market during the forecasted period of 2020-2030 is 14.76%
Global stomach cancer market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the stomach cancer market in 2022.
Increasing lifestyle changes such as smoking and alcoholism, an increase in obesity, and an increasing prevalence of gastroesophageal reflux disease all act as risk factors for gastric cancer.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Stomach Cancer Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Stomach Cancer Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Stomach Cancer Market - Global Market Analysis
6.1 Stomach Cancer - Global Market Overview
6.2 Stomach Cancer - Global Market and Forecast to 2030
7. Stomach Cancer Market – Revenue Analysis (USD Million) – By Type, 2020-2030
7.1 Overview
7.2 Adenocarcinomas
7.3 Gastrointestinal Stromal Tumors
7.4 Neuroendocrine Tumors
7.5 Lymphoma
7.6 Others
8. Stomach Cancer Market – Revenue Analysis (USD Million) – By Treatment, 2020-2030
8.1 Overview
8.2 Targeted and Immunotherapy Drugs
8.2.1 Monoclonal Antibody
8.2.2 Human Epidermal Growth Factor Receptor 2 (HER2)
8.2.3 Checkpoint Inhibitors
8.3 Chemotherapy and Combination Drugs
8.4 Others
9. Stomach Cancer Market – Revenue Analysis (USD Million) – By Route of Administration, 2020-2030
9.1 Overview
9.2 Oral
9.3 Parenteral
9.4 Others
10. Stomach Cancer Market – Revenue Analysis (USD Million) – By Distribution Channel, 2020-2030
10.1 Overview
10.2 Hospital Pharmacies
10.3 Retail Pharmacies
10.4 Online Pharmacies
11. Stomach Cancer Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis
11.1 North America
11.1.1 North America Stomach Cancer Market Overview
11.1.2 North America Stomach Cancer Market Revenue and Forecasts to 2030
11.1.3 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Type
11.1.4 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Treatment
11.1.5 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Route of Administration
11.1.6 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Distribution Channel
11.1.7 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Stomach Cancer Market
11.1.7.1.1 United States Stomach Cancer Market, by Type
11.1.7.1.2 United States Stomach Cancer Market, by Treatment
11.1.7.1.3 United States Stomach Cancer Market, by Route of Administration
11.1.7.1.4 United States Stomach Cancer Market, by Distribution Channel
11.1.7.2 Canada Stomach Cancer Market
11.1.7.2.1 Canada Stomach Cancer Market, by Type
11.1.7.2.2 Canada Stomach Cancer Market, by Treatment
11.1.7.2.3 Canada Stomach Cancer Market, by Route of Administration
11.1.7.2.4 Canada Stomach Cancer Market, by Distribution Channel
11.1.7.3 Mexico Stomach Cancer Market
11.1.7.3.1 Mexico Stomach Cancer Market, by Type
11.1.7.3.2 Mexico Stomach Cancer Market, by Treatment
11.1.7.3.3 Mexico Stomach Cancer Market, by Route of Administration
11.1.7.3.4 Mexico Stomach Cancer Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Stomach Cancer Market - Key Company Profiles
14.1 Bristol Myers Squibb Company
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Novartis AG
14.3 Merck and Co., Inc.
14.4 Eli Lilly and Company
14.5 Biocon
14.6 Teva Pharmaceutical Industries Ltd.
14.7 Celltrion Healthcare Co., Ltd.
14.8 Samsung Bioepis
14.9 Pfizer Inc.
14.10 Ipsen pharma
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
The List of Companies - Stomach Cancer Market
- Bristol Myers Squibb Company
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Biocon
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.
- Samsung Bioepis
- Pfizer Inc.
- Ipsen pharma.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For